Alto Neuroscience

ANRO · NYSE · United States

Share price · ANRO

$25.91-8.22 (-24.08%) 3M

close as of 2026-11-18 · 24h delayed · vol 986K (1.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ANRO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026-8.1%
  2. 11 Nov 2026+8.9%
  3. 9 Nov 2026+10.5%
  4. 6 Nov 2026+15.0%

    Nothing announced by ANRO that day or the session before.

  5. 23 Sep 2026-10.7%
  6. 13 Aug 2026+10.7%
  7. 13 Jul 2026+5.9%
  8. 9 Jun 2026+16.0%

    Nothing announced by ANRO that day or the session before.

  9. 13 Apr 2026+13.0%

    Nothing announced by ANRO that day or the session before.

  10. 11 Mar 2026+10.4%

Share of unusual movement by asset

For each asset, the share of ANRO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Pramipexole/ondansetron (ALTO-207)
events and moves
3shown from 8 days
ALTO-101
events and moves
2shown from 8 days
ALTO-203
events and moves
1shown from 8 days
ALTO-300
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—46%
Sessions with no dated event—52%

Assets

(6 total)
6Total Assets
0Approved
0Phase 3 / Filed
6Phase 1–2 / Early
4Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
Phase 2
First-in-class oral small molecule neural plasticity enhancerSmall molecule
Major Depressive DisorderBipolar Disorder
Phase 2
PDE4Small molecule
Schizophrenia
Cognitive Impairment Associated with Schizophrenia
Phase 2
Histamine H3 receptor (antagonist / inverse agonist)Small molecule
Major Depressive Disorder
Phase 2
Melatonergic (MT) receptors (agonist) + serotonin receptorSmall molecule
Major Depressive Disorder
Phase 2
Dopamine D2/D3 receptors (pramipexole component) and Neurokinin-1 (NK1) receptor (aprepitant component)Combination
Parkinson's Disease
Phase 2
Dopamine D3-preferring D3/D2 receptors (agonist) + 5-HT3 receptorSmall molecule
Major Depressive Disorder

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
ALTO-300Phase 2Major Depressive Disorder
Est. primary completion 2026-12 · NCT05922878 · CT.gov ↗
What to watch
2027 (2)
September 2027 (1)
ALTO-100Phase 2Bipolar Disorder I or II With a Major Depressive Episode
Est. primary completion 2027-09 · NCT06656416 · CT.gov ↗
What to watch
November 2027 (1)
Pramipexole/ondansetron (ALTO-207)Phase 2Treatment-resistant Depression (TRD)
Est. primary completion 2027-11 · NCT07553637 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 April 2026Topline resultALTO-101Phase 2 POC of ALTO-101 in CIAS did not reach statistical significance on its primary EEG or cognitive endpoints
Alto Neuroscience · Source ↗
3 June 2025Topline resultALTO-207Phase 2a of CTC-501 (now ALTO-207) met primary endpoint
Alto Neuroscience, Inc. · Source ↗

Financial reports

Quarterly & interim (12)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$18M$320M$25M-$21M operating cash flowreport ↗
View 11 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$22M$244M$28M-$20M operating cash flowreport ↗
2026-Q1—$20M$264M$26M-$27M operating cash flowreport ↗
2025-Q3—$11M$138M$14M-$9.9M operating cash flowreport ↗
2025-Q2—$13M$148M$18M-$14M operating cash flowreport ↗
2025-Q1—$10.0M$161M$15M-$17M operating cash flowreport ↗
2024-Q3—$13M$182M$17M-$12M operating cash flowreport ↗
2024-Q2—$13M$194M$16M-$12M operating cash flowreport ↗
2024-Q1—$9.9M$206M$13M-$11M operating cash flowreport ↗
2023-Q3—$8.0M$51M$9.1M-$7.8M operating cash flowreport ↗
2023-Q2—$7.1M$59M$8.7M-$6.6M operating cash flowreport ↗
2023-Q1—$5.6M$66M$7.3M-$7.5M operating cash flowreport ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$46M$177M$16M-$52M operating cash flowreport ↗

Alto Neuroscience reported no revenue disclosed for full-year 2025. R&D spend was $45.62M, down 2.9% YoY, and cash and equivalents totaled $176.98M at year-end versus approximately $169M in the prior year. The company reported a net loss of $63.24M, with a corresponding quarterly net burn of $63.24M.

Management expects the year-end cash balance to fund operations into 2028, covering four key pipeline data readouts. Alto acquired ALTO-207 for treatment-resistant depression, with a Phase 2b trial planned for the first half of 2026 and a Phase 3 trial by early 2027; an external PAX-D study published in The Lancet Psychiatry reported a 0.87 effect size for pramipexole. ALTO-101 received FDA Fast Track Designation for cognitive impairment associated with schizophrenia, with Phase 2 proof-of-concept topline data expected around the end of the first quarter of 2026. ALTO-300 Phase 2b major depressive disorder data are expected mid-2026, and ALTO-100 Phase 2b bipolar depression data in the second half of 2026.

View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$47M$169M$15M-$47M operating cash flowreport ↗
2023-FY—$30M$83M$9.1M-$33M operating cash flowreport ↗
2022-FY——$48M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 8 sales ($5.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-18Hanley Jr. Michael Conick · CHIEF OPERATING OFFICEROption exercise2,896$2.35$7KForm 4
2026-11-18Hanley Jr. Michael Conick · CHIEF OPERATING OFFICEROpen-market sale2,896$26.48$77KForm 4
2026-11-18Hanley Jr. Michael Conick · CHIEF OPERATING OFFICEROption exercise (derivative)2,896——Form 4
2026-11-17Hanley Jr. Michael Conick · CHIEF OPERATING OFFICEROption exercise2,104$2.35$5KForm 4
2026-11-17Hanley Jr. Michael Conick · CHIEF OPERATING OFFICEROpen-market sale2,104$26.82$56KForm 4
2026-11-17Hanley Jr. Michael Conick · CHIEF OPERATING OFFICEROption exercise (derivative)2,104——Form 4
2026-11-16Hanley Jr. Michael Conick · CHIEF OPERATING OFFICEROption exercise17,729$2.35$42KForm 4
2026-11-16Hanley Jr. Michael Conick · CHIEF OPERATING OFFICEROption exercise44,271$2.35$104KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 109 reporting institutions held 26.8M shares ($592.8M, 66.9% of shares outstanding).

#InstitutionSharesValue
1Alpha Wave Global, LP3,707,757$83.4M
2Commodore Capital LP2,723,196$61.2M
3Vestal Point Capital, LP2,064,075$46.4M
4PERCEPTIVE ADVISORS LLC2,009,893$45.2M
5Spruce Street Capital LP1,325,210$29.1M
6VANGUARD CAPITAL MANAGEMENT LLC1,207,025$27.1M
7FRANKLIN RESOURCES INC1,101,874$24.8M
8Vivo Capital, LLC1,035,551$23.3M
9ARMISTICE CAPITAL, LLC912,000$20.5M
10MILLENNIUM MANAGEMENT LLC821,982$18.5M
1172 Investment Holdings, LLC667,778$15.0M
12BlackRock, Inc.666,188$15.0M
13Ikarian Capital, LLC515,000$11.6M
14Point72 Asset Management, L.P.503,087$11.3M
15Venrock Adviser, LLC500,000$11.2M